As of 2024-12-12, the EV/EBITDA ratio of Cara Therapeutics Inc (CARA) is 0.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CARA's latest enterprise value is -22.41 mil USD. CARA's TTM EBITDA according to its financial statements is -84.83 mil USD. Dividing these 2 quantities gives us the above CARA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.5x - 9.8x | 8.5x |
| Forward P/E multiples | 13.1x - 19.1x | 16.3x |
| Fair Price | (19.61) - (14.54) | (18.50) |
| Upside | -7445.7% - -5546.0% | -7028.7% |
| Date | EV/EBITDA |
| 2024-12-10 | 0.26 |
| 2024-12-09 | 0.25 |
| 2024-12-06 | 0.26 |
| 2024-12-05 | 0.26 |
| 2024-12-04 | 0.26 |
| 2024-12-03 | 0.26 |
| 2024-12-02 | 0.25 |
| 2024-11-29 | 0.24 |
| 2024-11-27 | 0.25 |
| 2024-11-26 | 0.25 |
| 2024-11-25 | 0.24 |
| 2024-11-22 | 0.24 |
| 2024-11-21 | 0.24 |
| 2024-11-20 | 0.24 |
| 2024-11-19 | 0.24 |
| 2024-11-18 | 0.25 |
| 2024-11-15 | 0.24 |
| 2024-11-14 | 0.23 |
| 2024-11-13 | 0.23 |
| 2024-11-12 | 0.22 |
| 2024-11-11 | 0.22 |
| 2024-11-08 | 0.22 |
| 2024-11-07 | 0.21 |
| 2024-11-06 | 0.24 |
| 2024-11-05 | 0.25 |
| 2024-11-04 | 0.25 |
| 2024-11-01 | 0.24 |
| 2024-10-31 | 0.24 |
| 2024-10-30 | 0.25 |
| 2024-10-29 | 0.26 |
| 2024-10-28 | 0.26 |
| 2024-10-25 | 0.26 |
| 2024-10-24 | 0.27 |
| 2024-10-23 | 0.26 |
| 2024-10-22 | 0.26 |
| 2024-10-21 | 0.27 |
| 2024-10-18 | 0.27 |
| 2024-10-17 | 0.26 |
| 2024-10-16 | 0.27 |
| 2024-10-15 | 0.27 |
| 2024-10-14 | 0.27 |
| 2024-10-11 | 0.27 |
| 2024-10-10 | 0.27 |
| 2024-10-09 | 0.27 |
| 2024-10-08 | 0.27 |
| 2024-10-07 | 0.26 |
| 2024-10-04 | 0.26 |
| 2024-10-03 | 0.26 |
| 2024-10-02 | 0.25 |
| 2024-10-01 | 0.25 |